Radon Health Risks: What the Evidence Actually Says About Lung Cancer

We may earn commission from links on this page. Lead-form submissions are forwarded to local inspector partners. How we research and review.

Radon is the second leading cause of lung cancer in the United States behind smoking, and the leading cause among non-smokers. The EPA estimates approximately 21,000 lung cancer deaths per year in the U.S. are attributable to radon exposure. Behind these aggregate numbers is a well-characterized biological mechanism, a measurable dose-response relationship, and a clear pattern of who is most at risk. This guide walks through what the evidence actually supports about radon and lung cancer, the EPA action level math, and how to think about risk without sliding into either panic or dismissal.

InspectandTest is an independent editorial team. We are not medical professionals or radiation health physicists. This guide synthesizes EPA, WHO, NCI (National Cancer Institute), and ATSDR documentation. For specific medical questions about radon exposure history, consult a clinician with environmental medicine experience.

The biological mechanism

Radon-222 is a noble gas – chemically inert and non-reactive. The gas itself does not cause cancer through direct chemical interaction with biological tissue. The cancer-causing agents are the radioactive solid decay products that radon produces:

1. Radon-222 atom decays by alpha emission (half-life 3.8 days) into polonium-218.
2. Polonium-218 decays by alpha emission (half-life 3.1 minutes) into lead-214.
3. Lead-214 decays by beta emission (half-life 26.8 minutes) into bismuth-214.
4. Bismuth-214 decays by beta emission (half-life 19.9 minutes) into polonium-214.
5. Polonium-214 decays by alpha emission (half-life 0.16 milliseconds) into lead-210.
6. Lead-210 has a much longer half-life (22 years) and is no longer dynamically relevant for inhalation cancer risk.

The first four decay products are short-lived radioactive solids that exist as charged particles attaching to ambient dust, aerosols, and water vapor in indoor air. When inhaled, the contaminated dust deposits in lung tissue, particularly in the bronchial epithelium where airway branching slows airflow.

Once deposited, the polonium-218 and polonium-214 emit alpha particles. Alpha particles have low penetration distance (roughly 50 microns in tissue) but very high biological damage per particle. Each alpha hit on a cell can cause double-strand DNA breaks, chromosomal damage, and the kind of cellular damage that, accumulated over years, increases the probability of cancerous transformation.

The cancer that results is lung cancer – specifically squamous cell carcinoma and small cell carcinoma of the bronchial epithelium. Adenocarcinoma is less commonly attributed to radon. Lung cancers from radon exposure are histologically indistinguishable from lung cancers from smoking; the attribution is statistical rather than diagnostic.

The dose-response relationship

Decades of epidemiological research, primarily from underground miners and large residential cohort studies, have established a dose-response relationship between cumulative radon exposure and lung cancer incidence. The relationship is approximately linear (no threshold) within the range of measured residential exposures. There is no demonstrated safe exposure level; risk increases continuously with cumulative dose.

EPA risk estimates per 1,000 people exposed over a lifetime (approximately 70 years):

For comparison, the lifetime cancer risk from a CT scan is approximately 1 in 1,000 to 1 in 10,000. Radon at the EPA action level represents a substantially higher cumulative risk over a lifetime.

The smoking interaction

The interaction between smoking and radon exposure is multiplicative rather than additive. The biological reasons include:

• Impaired mucociliary clearance. Smoking damages the lung’s natural ability to clear inhaled particles. Radon progeny that would be cleared from a healthy lung remain longer in a smoker’s lung, increasing radiation exposure.
• Pre-existing DNA damage. Smoking causes its own DNA damage to bronchial epithelial cells. Radon-induced damage on top of smoking-damaged tissue produces synergistic effects rather than independent additive effects.
• Increased cell turnover. Damaged smoker lung tissue has higher cell division rates, which is when DNA damage becomes carcinogenic mutations.

The practical implication for households: if anyone in the home is a current or recent smoker, the radon mitigation threshold should drop. The 4.0 pCi/L EPA action level is calibrated for a general population including the smoking interaction, but the smoker’s individual risk at 4.0 pCi/L is high enough that mitigation at lower levels (2.0 pCi/L or below) is reasonable.

Who is at higher individual risk

Several populations warrant aggressive response to elevated radon at lower thresholds:

• Smokers and recent ex-smokers. Multiplicative risk interaction.
• Children. More breathing per body weight, more sensitive developing tissue, more lifetime years for cumulative damage.
• People with chronic lung conditions. COPD, emphysema, severe asthma all share underlying lung tissue compromise.
• Long-term residents of the same home. Cumulative dose is duration times concentration; 30+ years in the same elevated-radon home is significantly higher cumulative dose than 5 years.
• Basement office and bedroom users. Radon concentrations are highest at the lowest occupied levels; people who spend 8+ hours per day in basements are at higher exposure than people who spend most of their time on upper floors.

Symptoms and screening

Radon-induced lung cancer has no specific symptoms that distinguish it from other lung cancers. The symptoms are general lung cancer symptoms: persistent cough, blood in sputum, shortness of breath, chest pain, recurrent respiratory infections, unexplained weight loss. By the time symptoms appear, cancer is typically at an advanced stage.

The CDC and the American Cancer Society do not currently recommend lung cancer screening based on radon exposure history alone. The current screening criteria (low-dose CT for adults aged 50-80 with significant smoking history) do not specifically include non-smoking radon-exposed populations. The right preventive action is: test for radon, mitigate if elevated, and incorporate radon exposure history into your overall risk profile when discussing screening with a primary care physician.

The pragmatic homeowner conclusion

The radon-lung-cancer connection is well-established science with decades of supporting epidemiology. The mechanism is biological and the dose-response is measurable. None of this is controversial in mainstream medicine.

The pragmatic action items:

1. Test your home. If you have not, do it now. Our radon detector buyer’s guide walks through testing options.
2. Mitigate elevated levels. If your test is above 4.0 pCi/L (or above 2.0 pCi/L if you have smokers or children in the home), schedule mitigation. Mitigation typically costs $1,200 to $2,500.
3. Re-test annually after mitigation. Mitigation systems can degrade or fail. Annual confirmation that the system is working is the maintenance standard.
4. Inform new occupants. Real estate transactions in most states require disclosure of known radon test results. New buyers and renters need the information to make informed decisions.

References

• U.S. Environmental Protection Agency
• Centers for Disease Control and Prevention
• IICRC
• OSHA